Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Has the 6-min walk distance run its course?

McLaughlin VV.

Chest. 2012 Dec;142(6):1363-1365. doi: 10.1378/chest.12-1110. No abstract available.

PMID:
23208324
2.

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.

Chest. 2012 Dec;142(6):1383-1390. doi: 10.1378/chest.11-2212.

PMID:
22628490
3.

[The current pharmacotherapy of pulmonary arterial hypertension].

Betkier-Lipińska K, Ryczek R, Cwetsch A.

Pol Merkur Lekarski. 2015 Jan;38(223):34-8. Review. Polish.

PMID:
25763586
4.

Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.

Burger CD.

Ann Am Thorac Soc. 2015 Jun;12(6):959. doi: 10.1513/AnnalsATS.201503-114LE. No abstract available.

PMID:
26075561
5.

Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.

Ann Am Thorac Soc. 2015 Jun;12(6):960. doi: 10.1513/AnnalsATS.201505-263LE. No abstract available.

PMID:
26075562
6.

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.

Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Fujita J, Kataoka M, Kuwana M, Satoh T, Fukuda K.

BMC Pulm Med. 2015 May 14;15:62. doi: 10.1186/s12890-015-0037-8.

7.

[Current issues in pulmonary hypertension].

Forster T.

Orv Hetil. 2012 Apr 22;153(16):603-6. doi: 10.1556/OH.2012.29358. Review. Hungarian.

PMID:
22510315
8.
9.

[Is pulmonary hypertension diagnosed correctly and early enough? Highly relevant dilemma: incomplete diagnostic, inaccurate treatment].

Rosenkranz S.

Dtsch Med Wochenschr. 2013 Sep;138(37):1820. doi: 10.1055/s-0032-1329060. Epub 2013 Sep 4. German. No abstract available.

PMID:
24006160
10.

Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB; PACES Study Group.

J Heart Lung Transplant. 2014 Jul;33(7):689-97. doi: 10.1016/j.healun.2014.02.019. Epub 2014 Feb 22.

PMID:
24815795
11.

Gender-related differences in pulmonary arterial hypertension targeted drugs administration.

Marra AM, Benjamin N, Eichstaedt C, Salzano A, Arcopinto M, Gargani L, D Alto M, Argiento P, Falsetti L, Di Giosia P, Isidori AM, Ferrara F, Bossone E, Cittadini A, Grünig E.

Pharmacol Res. 2016 Dec;114:103-109. doi: 10.1016/j.phrs.2016.10.018. Epub 2016 Oct 19. Review.

PMID:
27771466
12.

Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.

Franklin WJ, Parekh DR, Safdar Z.

Postgrad Med. 2011 Nov;123(6):32-45. doi: 10.3810/pgm.2011.11.2493.

PMID:
22104452
13.

Pulmonary hypertension in older children: new approaches and therapies.

Abman SH.

Paediatr Respir Rev. 2006;7 Suppl 1:S177-9. Epub 2006 Jun 5. Review. No abstract available.

PMID:
16798555
14.

Pathways in pulmonary arterial hypertension: the future is here.

Sitbon O, Morrell N.

Eur Respir Rev. 2012 Dec 1;21(126):321-7. doi: 10.1183/09059180.00004812. Review.

15.

[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].

Humbert M.

Rev Med Interne. 2007 Dec;28 Suppl 4:S273-6. Epub 2007 Oct 8. French. No abstract available.

PMID:
17961866
16.

[What is new in the treatment of pulmonary artery hypertension?].

Pulido Zamudio T.

Arch Cardiol Mex. 2003 Apr-Jun;73 Suppl 1:S121-4. Review. Spanish.

PMID:
12966661
17.

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.

Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ; FREEDOM-C2 Study Team.

Chest. 2013 Sep;144(3):952-958. doi: 10.1378/chest.12-2875.

PMID:
23669822
18.

Why patients who die of worsening pulmonary arterial hypertension are not on parenteral prostacyclin analog treatment?

Tonelli AR, Dweik RA.

J Heart Lung Transplant. 2014 Feb;33(2):221. doi: 10.1016/j.healun.2013.10.007. Epub 2013 Oct 3. No abstract available.

19.

Pulmonary arterial hypertension : a comprehensive review of pharmacological treatment.

Berman Rosenzweig E, Barst RJ.

Treat Respir Med. 2006;5(2):117-27. Review.

PMID:
16512692
20.

Oral prostacyclin therapy for pulmonary arterial hypertension: another step forward.

Waxman AB.

Circulation. 2013 Feb 5;127(5):563-5. doi: 10.1161/CIRCULATIONAHA.112.000675. Epub 2013 Jan 10. No abstract available.

Supplemental Content

Support Center